2/19/2013 9:34:30 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company focused on developing first in class therapies for the treatment of cancer, today provided an update on its strategic business goals for 2013. “I am pleased to report that Rexahn is positioned to achieve significant strategic milestones in 2013. The infusion of $9 million from our recently completed public offering and research funding from Teva Pharmaceuticals for RX-3117 will enable the company to accelerate the clinical development of Archexin, RX-3117, and RX-5902, while advancing three pre-clinical compounds closer to clinical development,” said Peter D. Suzdak, Ph.D., CEO of Rexahn. “Our anticipated clinical and pre-clinical development progress will both increase shareholder value and support our strategic partnering efforts,” added Dr. Suzdak.
comments powered by